GXP-PHARMA SUPPORT ApS Financials, key figures and credit report
Gross profit 128.5 kDKK FY 2025 -63.9% vs 2024
EBIT - 395.6 kDKK FY 2025 -13.7% vs 2024
Net debt 16.4 kDKK FY 2025 +103.4% vs 2024
Quick ratio 1.4 FY 2025 -0.9 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 382.15 | 211.19 | 360.87 | 355.76 | 128.52 |
| Costs of management | - 229.29 | - 269.61 | - 234.13 | ||
| Employee benefit expenses | - 703.54 | - 524.11 | |||
| EBIT | 152.87 | -58.41 | 126.74 | - 347.78 | - 395.59 |
| Other financial income | 402.55 | 18.53 | 347.97 | 144.53 | 31.59 |
| Other financial expenses | -7.61 | - 400.34 | -3.73 | -10.12 | -5.81 |
| Pre-tax profit | 547.81 | - 440.23 | 470.98 | - 213.36 | - 369.82 |
| Income taxes | - 122.14 | 94.68 | - 103.63 | 46.93 | 55.32 |
| Net earnings | 425.67 | - 345.55 | 367.36 | - 166.43 | - 314.50 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 434.59 | 181.13 | 208.74 | 20.63 | 5.81 |
| Current amounts owed by group member comp. | 45.84 | ||||
| Current other receivables | 178.95 | 0.80 | 18.91 | 18.91 | |
| Current deferred tax assets | 96.85 | 48.05 | 55.55 | ||
| Short term receivables total | 613.54 | 277.98 | 209.54 | 87.58 | 126.11 |
| Other current investments | 1 516.89 | 629.91 | 1 243.05 | 477.65 | |
| Cash and bank deposits | 46.22 | 196.70 | 27.99 | 80.92 | 71.85 |
| Cash and cash equivalents | 1 563.12 | 826.62 | 1 271.04 | 558.57 | 71.85 |
| Balance sheet total (assets) | 2 176.66 | 1 104.59 | 1 480.58 | 646.16 | 197.97 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 |
| Shares repurchased | 600.00 | ||||
| Retained earnings | 192.20 | 617.87 | - 327.68 | 39.68 | - 126.75 |
| Profit of the financial year | 425.67 | - 345.55 | 367.36 | - 166.43 | - 314.50 |
| Shareholders equity total | 1 117.87 | 772.32 | 1 139.68 | 373.24 | 58.75 |
| Provisions | -0.00 | ||||
| Non-current liabilities total | |||||
| Current trade creditors | 13.00 | 14.00 | 14.00 | 14.00 | 14.00 |
| Current owed to participating | 1.69 | ||||
| Current owed to group member | 556.31 | 79.65 | 128.30 | 78.35 | 88.21 |
| Short-term deferred tax liabilities | 116.48 | 2.21 | |||
| Other non-interest bearing current liabilities | 371.32 | 238.63 | 196.40 | 180.56 | 37.01 |
| Current liabilities total | 1 058.79 | 332.27 | 340.91 | 272.91 | 139.22 |
| Balance sheet total (liabilities) | 2 176.66 | 1 104.59 | 1 480.58 | 646.16 | 197.97 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated